Quarterly ResultMay 6, 2026, 07:37 AM
Royalty Pharma Q1 Portfolio Receipts +10% to $925M; Raises FY26 Guidance
AI Summary
Royalty Pharma plc reported strong financial results for the first quarter of 2026, with Portfolio Receipts growing 10% to $925 million and Royalty Receipts increasing 13% to $887 million. The company also raised its full-year 2026 Portfolio Receipts guidance to a range of $3,325 million to $3,450 million. Key highlights included significant transaction activity, with up to $1.25 billion in new royalty deals, and positive clinical and regulatory developments across its portfolio, such as the FDA approval of Avlayah and positive Phase 3 results for daraxonrasib.
Key Highlights
- Q1 2026 Portfolio Receipts grew 10% to $925 million.
- Q1 2026 Royalty Receipts increased 13% to $887 million, driven by Tremfya, Voranigo, and Evrysdi.
- Net cash provided by operating activities rose 20% to $718 million in Q1 2026.
- Adjusted EBITDA (non-GAAP) increased 21% to $889 million in Q1 2026.
- Raised full-year 2026 Portfolio Receipts guidance to $3,325 million to $3,450 million.
- Announced up to $1.25 billion in new royalty transactions, including R&D co-funding with Johnson & Johnson ($500M) and Teva ($500M).
- Repurchased 1.1 million Class A ordinary shares for $50 million in Q1 2026.
- Paid a quarterly dividend of $0.235 per share, totaling $136 million in Q1 2026.